West Pharmaceutical Services, Inc. (NYSE:WST) Given Consensus Rating of “Moderate Buy” by Analysts

West Pharmaceutical Services, Inc. (NYSE:WST) has been assigned an average recommendation of “Moderate Buy” from the fifteen brokerages that are covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $368.0769.

WST has been the topic of several research analyst reports. Barclays upgraded shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $310.00 to $400.00 in a research report on Tuesday, June 9th. TD Cowen reissued a “buy” rating on shares of West Pharmaceutical Services in a research report on Wednesday, July 15th. Citigroup increased their price objective on West Pharmaceutical Services from $400.00 to $412.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Evercore restated an “outperform” rating and set a $425.00 price objective on shares of West Pharmaceutical Services in a research report on Monday, July 27th. Finally, Morgan Stanley lifted their target price on West Pharmaceutical Services from $325.00 to $365.00 and gave the company an “equal weight” rating in a research note on Thursday, July 9th.

West Pharmaceutical Services Trading Down 0.0%

Shares of WST opened at $339.90 on Monday. The business’s 50-day moving average price is $350.55 and its 200 day moving average price is $307.32. The stock has a market capitalization of $23.92 billion, a P/E ratio of 43.52, a P/E/G ratio of 2.38 and a beta of 1.14. West Pharmaceutical Services has a 1-year low of $223.83 and a 1-year high of $386.00. The company has a current ratio of 2.82, a quick ratio of 2.12 and a debt-to-equity ratio of 0.07.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share for the quarter, topping the consensus estimate of $2.08 by $0.29. The business had revenue of $872.30 million for the quarter, compared to the consensus estimate of $839.98 million. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The firm’s quarterly revenue was up 13.8% compared to the same quarter last year. During the same period last year, the firm posted $1.84 earnings per share. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Analysts expect that West Pharmaceutical Services will post 8.93 earnings per share for the current year.

West Pharmaceutical Services Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th were given a dividend of $0.22 per share. The ex-dividend date of this dividend was Wednesday, July 29th. This represents a $0.88 dividend on an annualized basis and a yield of 0.3%. West Pharmaceutical Services’s payout ratio is presently 11.27%.

Institutional Investors Weigh In On West Pharmaceutical Services

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Elyxium Wealth LLC acquired a new position in shares of West Pharmaceutical Services in the fourth quarter worth $25,000. CYBER HORNET ETFs LLC acquired a new stake in West Pharmaceutical Services during the second quarter valued at $25,000. Cornerstone Planning Group LLC grew its stake in West Pharmaceutical Services by 90.9% in the first quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 50 shares in the last quarter. Bayban acquired a new position in West Pharmaceutical Services in the 4th quarter worth about $27,000. Finally, Avalon Trust Co acquired a new position in West Pharmaceutical Services in the 2nd quarter worth about $28,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.